GlassScriptPhysician profile
Sarah Cannon
NPI 1821319229
$8,358.52
in general payments reported to CMS, 2019-2025
25 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $427 · 2021: $928 · 2022: $1,207 · 2023: $2,054 · 2024: $2,006 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,295 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,295.16 |
| Education | $110.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,849.60 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,420.32 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $790.80 | 2021-2025 | Winlevi, Absorica Ld |
| Genzyme Corporation | $563.57 | 2019-2025 | |
| Lilly USA, LLC | $544.84 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $535.30 | 2019-2025 | Dysport, Nemluvio, Aklief |
| Pfizer INC. | $506.56 | 2019-2025 | |
| Amgen INC. | $383.70 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $352.51 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $251.75 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $226.07 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $184.20 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $162.94 | 2023-2024 | Sotyktu |
| Almirall LLC | $119.88 | 2021-2024 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $115.05 | 2019-2025 | Jublia, Cabtreo, Siliq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $85.28 | 2022-2023 | Vtama |
| Ucb, INC. | $56.41 | 2020-2024 | Bimzelx |
| Organon LLC | $50.39 | 2025 | Vtama |
| Merz North America, INC. | $38.09 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| Verrica Pharmaceuticals INC. | $23.53 | 2023 | Ycanth |
| Allergan, INC. | $19.90 | 2022 | |
| Celgene Corporation | $18.69 | 2019 | |
| Strata Skin Sciences, INC. | $17.47 | 2023 | Xtrac |
| Biofrontera INC. | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.